How did COVID-19 impact 3M's sales in the second quarter of 2020?

COVID-19 had a mixed impact. While it drove strong demand for personal safety products like respirators, it negatively affected sales in several other segments, including Oral Care, Automotive and Aerospace, and Consumer Goods, due to decreased consumer and industrial demand and disruptions in supply chains.

What was the financial impact of the drug delivery business divestiture?

3M completed the sale of substantially all of its drug delivery business in May 2020 for $617 million. This resulted in a pre-tax gain of $387 million, which was recognized in the second quarter of 2020.

How did 3M manage its liquidity and capital resources during the quarter?

3M maintained a strong liquidity position with $4.5 billion in cash, cash equivalents, and marketable securities. The company issued $1.75 billion in registered notes in March 2020 to bolster liquidity in response to COVID-19 uncertainty. It also suspended its share repurchase program in March 2020 but continued to pay dividends to shareholders.

What were the key drivers of the year-over-year increase in diluted EPS?

The increase in diluted EPS was driven by a combination of factors, including the gain from the sale of the drug delivery business, cost-saving initiatives, and a lower effective tax rate. These benefits more than offset the impact of lower organic sales and higher restructuring charges.

MMM 10-Q Quarterly Report Q2 FY2020 — Revenue, Net Income, EPS

Summary

3M Company reported its second-quarter 2020 financial results, showcasing resilience amid the COVID-19 pandemic. Net sales for the quarter declined by 12.2% to $7.18 billion, impacted by broad-based weakness across several industrial and consumer markets. However, the company saw strong demand in its Personal Safety division, largely driven by increased sales of respirators. Despite the sales dip, 3M demonstrated improved profitability, with diluted earnings per share (EPS) increasing by 15.6% to $2.22. This improvement was partly due to a significant gain from the sale of its drug delivery business and effective cost management initiatives. The company maintained a strong liquidity position and continued its commitment to shareholder returns through dividends, though it suspended its share repurchase program due to pandemic-related uncertainty. The company's focus remains on navigating the challenging economic environment while investing in key growth areas.

Financial Highlights

53 data points

Beta

Revenue

$7.18B

0.5% Gross Margin

Net Income

$1.31B

0.2% Net Margin

EPS (Diluted)

$2.25

Total Assets

$45.08B

Free Cash Flow

$1.53B

Financial Statements

Beta

Revenue	$7.18B
Cost of Revenue	$3.81B
Gross Profit	$3.37B
SG&A Expenses	$1.59B
Operating Expenses	$5.44B
Operating Income	$1.74B
Interest Expense	$137.00M
Net Income	$1.31B
EPS (Basic)	$2.26
EPS (Diluted)	$2.25
Shares Outstanding (Basic)	577.00M
Shares Outstanding (Diluted)	580.80M

Key Highlights

1Net sales decreased by 12.2% to $7.18 billion for the second quarter of 2020.
2Diluted earnings per share (EPS) increased by 15.6% to $2.22 compared to the prior year quarter.
3Personal Safety segment saw strong demand for respirators due to COVID-19, while other segments experienced declines.
4The company completed the sale of its drug delivery business, recognizing a significant pre-tax gain of $387 million.
5Operating income margins increased to 24.3% on a GAAP basis, but decreased to 19.6% on an adjusted basis excluding special items.
63M maintained a strong liquidity position, with $4.5 billion in cash, cash equivalents, and marketable securities as of June 30, 2020.
7The company suspended its share repurchase program in March 2020 due to COVID-19 uncertainty.

3M CO Quarterly Report for Q2 Ended Jun 30, 2020

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions